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Background: Some peptides, which regulate the metabolic balance, are thought to play important roles in
nutritional disorders and systemic inflammation in COPD. Treatment of rats with obestatin decreased body-weight
gain. Obestatin was also found to be correlated with inflammation in rheumatoid arthritis. The aims of this study
were to investigate the level of circulating obestatin in COPD and to analyze the relationship among obestatin and
nutritional status, and systemic inflammation.
Methods: 32 COPD patients with BMI less than 20 kg/m2 and 22 normal controls were included. Body composition
was estimated using “foot-to-foot” BIA technology. Circulating obestatin was determined with enzyme-linked
immunosorbent assay. Pulmonary function, TNF-α and C reactive protein were also measured.
Results: The level of circulating obestatin was higher in COPD with underweight than that in normal control
(5562.75 ± 3435.43 pg/ml in COPD, 3663.90 ± 2313.95 pg/ml in controls, p = 0.028). BMI, Waist circumference, hip
circumference, bodyFAT and FAT% in COPD group were lower than those in normal control. Positive correlation
was found among circulating C reactive protein, TNF-α and obestatin. There was no significant correlation among
BMI, pulmonary function and obestatin.
Conclusions: This study shows that circulating obestatin is higher in underweight COPD patients, and positively
correlated to systemic inflammation, but not to nutritional status.
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Disorders of nutritional status are regarded as common
phenomena resulting from chronic obstructive pulmon-
ary disease (COPD) [1]. Malnutrition is a major factor
that increases mortality in COPD, whose frequency was
reported between 20% and 40% [1,2]. Moreover, poor
nutritional status increased the risk of acute exacerbation,
which results in decreased lung function and life quality
of the patients [2,3]. Thus, understanding the mechanism
of malnutrition in COPD may be helpful to manage this
disease. However, the mechanism of COPD related mal-
nutrition largely remains unknown at present. Although a
previous research showed that systemic inflammation
is one of the main factors leading to malnutrition in
COPD [4], understanding how the systemic inflammation* Correspondence: xiaoyangliao@hotmail.com; luofengming@hotmail.com
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stated.regulates malnutrition in COPD is unclear. Some studies
reported that digestive tract cells or adipocytes secrete
peptides regulating the metabolic balance and inflamma-
tion process, and thus play important roles in the nutri-
tion disorder in COPD [5,6]. However, previously only a
few of these peptides have been studied in COPD.
Obestatin is a putative hormone secreted by the cells
of the stomach and small intestine of several mammals
including humans. The gene that encodes obestatin also
encodes ghrelin, a peptide hormone that increases appe-
tite [7]. The precursor protein breaks into two peptides,
ghrelin and obestatin [7]. Ghrelin increases the food in-
take and decreases energy expenditure, and thus causes
weight gain. In contrast to ghrelin, obestatin acts as an
anorexic hormone by decreasing food intake, gastric
emptying activities, and jejunal motility, thus, leading to
body-weight loss [7]. Although circulating ghrelin was
reported to take a part in the malnutrition in COPDThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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with COPD nutritional status remain unknown.
Obestatin was also reported to modulate the inflam-
mation process in some diseases. Kellokoski et al. [10]
reported that obestatin decreased vascular cell adhesion
molecule-1 (VCAM-1) expression in the presence of
tumor necrosis factor-α (TNF-α). Although there was no
significant difference in the level of obestatin between
normal control and rheumatoid arthritis (RA), a disease
with systemic inflammation, obestatin was found to be
higher in RA than in Behçet’s disease (BD), the other
chronic inflammation disease. Furthermore, the level of
obestatin in other diseases with systemic inflammation
has not been investigated yet. In addition, obestatin was
found to be positively correlated with erythrocyte sedi-
mentation rate in the RA group, the level of IL-6 in the
BD group, and with the level of TNF-α in the control
group. Whether obestatin correlates with inflammatory
markers in COPD remains unknown.
Therefore, the aim of this study was to investigate the
relationship between the level of plasma obestatin and




This study was approved by the medical ethics commit-
tee of the West China Hospital, Sichuan University. All
subjects signed consent for taking part into this study.
2,000 people in 2 communities were screened for COPD
according to the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) criteria [11]. Patients that had
known conditions which may affect plasma obestatin
levels such as gastrointestinal disease, liver disease, kid-
ney disease, thyroid disease, metabolic disease, or other
lung diseases were excluded [12,13]. Therefore, 32
COPD patients with BMI less than 20 were included in
this study. None of these patients were receiving nutri-
tional support therapy or taking any medication at the
time of evaluation. 22 aged and gender-matched healthy
people from these communities, with normal physical
examination and laboratory data and without medical ill-
nesses, were enrolled as control group.
Pulmonary function test
FVC and FEV1 were measured using standard spiromet-
ric techniques (MicroLoop; Micro Medical Ltd, Kent,
UK). The test was performed according to ERS criteria
[14]. The reference values employed were proposed by
Zheng et al. [15].
Body composition
Body height was determined to the nearest 0.5 cm with
subjects standing barefoot. Body composition in thisstudy was estimated using “foot-to-foot” bioelectrical
impedance analysis (BIA) technology (QuickMedical,
Snoqualmie, SE) while subjects were standing on blocks of
solid metal. Lightweight, FM, Fat Free Mass, %fat and
BMI were automatically calculated by the machine after
age, height and gender were entered and standard cal-
culation model was selected following manufacturer’s
instructions.
Sample collection
Fasting (from 9:00 p.m. of the previous night) blood
samples was obtained by vein puncture at 8:00 a.m., cen-
trifuged at 1,600 × g for 15 minutes at 4°C, The plasma
was collected and stored at − 70°C.
Obestatin assay
Obestatin was assayed with a sandwich enzyme linked
immunosorbent assay kit (ELISA, Westang Bio-Tech Co.
Ltd, Shanghai, China). The minimum detectable concen-
tration was 100 pg/ml.
TNF-α and C reactive protein (CRP) assays
Plasma TNF-α was measured using a high sensitivity
ELISA (R&D, Minneapolis, MN, USA) according to the
manufacturer’s procedure. The intra-and inter-assay var-
iations were 6.0 and 7.5%, respectively. The minimum
detectable concentration was 4.4 pg/ml. CRP in plasma
was measured using an ELISA kit (Westang Bio-Tech
Co. Ltd, Shanghai, China).
Statistical analysis
Results are given as mean ± SD. Differences between the
groups were statistically analyzed using an unpaired
Student’s t test. Correlations were performed by bivariate
Pearson correlation test. Significance was determined at
the level of 5%. Data were analyzed with SPSS (Statistical
Package for the Social Sciences, version 10.0 for Win-
dows, SPSS Inc., Chicago, IL).
Results
Characteristics of the study subjects
Clinical characteristics of both the COPD patients and
the control group are shown in Table 1. The COPD pa-
tients had airflow limitation and the control subjects had
normal FEV1 values. BMI, waist circumference and hip
circumference in the COPD group were lower than
those in the control group. No significant differences
were found regarding blood total cholesterol, triglycer-
ide, creatinine, uric acid and blood urea nitrogen.
Plasma obestatin in control group and COPD group
Plasma obestatin was assayed by ELISA as described in
Methods. As shown in Figure 1, the level of plasma
obestatin was significantly higher in the COPD group
Table 1 Characteristics of the study subjects
Control COPD
Age, y 60.41 ± 6.60 59.78 ± 8.71
Sex, male/female 13/9 20/12
Smoking history, pack/year 12.96 ± 18.19 11.40 ± 16.39
BMI (kg/m2) 22.66 ± 2.96 18.99 ± 1.00*
FFM, kg 24.96 + 4.79 24.63 + 5.20*
Percent body fat, % weight 55.42 + 7.70 49.88 + 8.91*
Waist circumference (cm) 76.78 ± 9.64 68.13 ± 6.39*
Hip circumference (cm) 89.27 ± 7.12 84.54 ± 4.34*
Waist hip ratio 0.86 ± 0.06 0.81 ± 0.05*
FEV1/FVC, % 84.41 ± 4.58 63.66 ± 6.24*
FEV1, % predicted 85.51 + 20.23 69.81 + 15.99
Total cholesterol (mmol/L) 4.81 ± 1.16 4.68 ± 0.95
Triglyceride (mmol/L) 1.33 ± 0.53 1.04 ± 0.40
Creatinine (μmol/L) 88.32 ± 11.41 89.63 ± 16.78
Uric acid (μmol/L) 313.41 ± 68.12 302.31 ± 60.16
Blood urea nitrogen (μmol/L) 5.59 ± 1.33 5.72 ± 1.11
BMI, Body mass index; FFM, free fat mass; FEV1, forced expiratory volume in
one second; FVC, forced vital capacity; COPD, chronic obstructive pulmonary
disease. Values presented are mean ± SD. *indicate significant differences
compared with normal control group (p < 0.05).
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3435.43 pg/ml in COPD, 3663.90 ± 2313.95 pg/ml in
controls, p = 0.028).
Plasma obestatin does not correlate with BMI and other
nutritional parameters
Treatment of rats with obestatin suppressed appetite,
inhibited jejunal contraction, and decreased body-weight
gain. We postulated that increased obestatin resulted inFigure 1 Plasma obestatin level was significantly higher in
COPD group than in age matched controls. * indicate significant
differences between control and COPD group (p < 0.05). COPD,
chronic obstructive pulmonary disease.malnutrition in COPD, so we further investigated this
trend. Correlation analysis was performed between obes-
tatin and COPD nutrition status. However, bivariate cor-
relate analysis did not show any significant correlation
between the level of plasma obestatin and BMI, % body
fat, FFM, waist circumference, hip circumference, and
waist hip ratio. No significant correlation was found be-
tween obestatin and cholesterol, triglyceride, glucose, or
insulin.
Plasma obestatin correlates with systemic inflammatory
markers
Systemic inflammation is a clinical characteristic of
COPD. Previous researches showed that obestatin cor-
related with inflammatory markers in RA patients.
Increased plasma obestatin may also correlate with in-
flammatory markers in COPD. As shown in Figure 2,
plasma obestatin was positively correlated with the sys-
temic inflammatory markers: CRP and TNF-α.
Plasma obestatin does not correlate with pulmonary
function in COPD
To further investigate whether the level of obestatin
correlated with airflow limitation, bivariate correlation
analysis was performed between the level of obestatin
and FEV1/FVC%. As shown in Figure 3, the level of
plasma obestatin does not correlate with this pulmonary
function parameter.
Discussion
In this study, we found that the level of plasma obestatin
was significantly higher in COPD patients than in the
control group. Significant correlation was found between
the level of plasma obestatin and the systemic inflamma-
tory markers: CRP and TNF-α. No significant correl-
ation was found between the level of plasma obestatin
and nutrition status parameters such as BMI, % body fat,
FFM, waist circumference, hip circumference, waist hip
ratio, cholesterol, triglyceride, glucose, or insulin. No sig-
nificant correlation was found between the level of
plasma obestatin and lung function.
Obestatin is a 23-amino acid peptide hormone re-
leased from the cells lining the stomach. Studies in
humans have shown that plasma obestatin levels are
significantly lower in obese subjects as compared to
lean controls, indicating a role for obestatin in body
weight regulation. Gao et al. [16] found the number of
obestatin-positive cells in gastric body mucosa was sig-
nificantly lower in overweight and obese patients than in
healthy controls with normal weight. The concentration
of plasma obestatin was also decreased in overweight
and obese patients and positively correlated with the
number of obestatin-positive cells in the gastric body
mucosa. The authors suggested that overweight and
Figure 2 Plasma obestatin correlates with circulating CRP and TNF-α (control group: Figure 2a and b. malnourished COPD patients:
Figure 2c and d). CRP, C-reactive protein; TNF, Tumour necrosis factor.
Figure 3 Plasma obestatin does not correlate with FEV1/FVC% in control group (Figure 3a) and malnourished COPD patients
(Figure 3b). FEV1, forced expiratory volume in one second; FVC, forced vital capacity.
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obestatin-positive cells in the gastric body mucosa. In
our study, the level of circulating obestatin was found to
be higher in COPD patients with malnutrition than in
the healthy control group. The exact mechanism of
obestatin increase in COPD with malnutrition is not
clear because the regulation of the expression of obesta-
tin remains unknown at present. It was reported that the
production of ghrelin, an adipokine derived from the
same gene as obestatin, was regulated by other adipo-
kines, (such as leptin) inflammation, or diet [17,18].
Zhang et al. [7] reported that although fasting led to
higher level of ghrelin, the serum level of obestatin was
constant after fasting in rats. These results suggested
that although they are encoded by the same gene, the
production of ghrelin and obestatin is regulated by dif-
ferent factors. Obestatin was found to be positively cor-
related with IL-6 in the BD patients, and with the level
of TNF-α in the control group. It was also correlated
with CRP and TNF-α in COPD. Increased obestatin may
then be the result of inflammation in COPD, a disease
with chronic systemic inflammation.
Obestatin was reported to suppress food intake, inhibit
jejunal contraction, and decrease weight gain [7]. Al-
though the level of plasma obestatin was higher in
COPD patients compared with age-matched controls,
no significant correlation was found between obestatin
and BMI, % body fat, FFM, waist circumference, hip
circumference, or waist hip ration in COPD. Although
Xin et al. [13] reported that the level of obestatin was
negatively correlated with BMI in chronic heart failure
(CHF) patients, plasma obestatin did not correlate with
BMI or other nutrition parameters in COPD in this study.
Other studies also found that obestatin was inversely
correlated with BMI in chronic kidney disease and
hemodialysis patients. Gao et al. [16] reported that nega-
tive correlation was found between circulating obestatin
levels and BMI in healthy subjects, but not in patients
with chronic atrophic gastritis. This result suggests that
obestatin expression in some diseases may be different
from healthy patients. Zhang et al. [7] found that obestatin
suppressed food intake in fasting mice and spontaneously
reduced weight gain at large doses in lean mice. Another
research demonstrated that obestatin exerted no effect
on food intake and body weight in rats [19]. Other authors
[14] found that Roux-en-Y gastric bypass (RYGB) surgery
and/or the weight loss resulted in the decrease of ghrelin
level but had no effect on obestatin levels. Thus, the
role of obestatin in energy metabolism still remains
uncertain.
Although the level of obestatin did not correlate with
COPD nutritional status, correlation analysis showed
that the level of plasma obestatin did positively correlate
with CRP and TNF-α in COPD patients. It was reportedthat ghrelin inhibited various inflammation processes in
arthritic rats, acute lung injury, and other inflammation
diseases [20,21]. Since obestatin is derived from the
same gene which also encodes ghrelin, it may play a role
in systemic inflammation in COPD. Until now, only a
few studies have investigated the role of obestatin in in-
flammation. Kellokoski et al. [10] reported that obestatin
did not influence the adhesion of monocytes. Although
obestatin treatment did not change the expression of
either intercellular adhesion molecule-1 (ICAM-1) or
monocyte chemoattractant protein-1 (MCP-1), obestatin
treatment together with TNF-α suppressed the expres-
sion of VCAM-1, but did not alter ICAM-1 or MCP-1
expressions. As TNF-α and other pro-inflammatory cy-
tokines increase in COPD, whether obestatin inhibits
systemic inflammation by suppressing the expression of
VCAM and other adhesion molecules requires further
investigation. Koca et al. [22] reported that no positive
correlation was found between the level of obestatin and
some inflammatory markers in two chronic inflamma-
tory diseases -RA and BD. This is different from our re-
sults. In their study, medications affecting the immune
system were administrated to RA and BD patients but
not to the control group. This may have affected the
level of obestatin in their RA and BD groups. In contrast
to our study in which no medication was administered
to the COPD group or the control group, Xin et al. [13]
reported that the level of obestatin was higher in CHF
patients with cachexia compared with non-cachexia and
normal controls. They also found that the level of
plasma obestatin had a negative correlation with BMI.
Since CHF is regarded as a disease with chronic systemic
inflammation [23,24], the different levels of plasma obes-
tatin in CHF patients and their negative correlation with
BMI may be the result of the systemic inflammation of
this disease.
Conclusion
The level of circulating obestatin was higher in the
COPD group compared with the control group. Obes-
tatin was positively correlated with COPD systemic
inflammation.
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